Alzheimer's disease, Dementia, Pathology, Pittsburgh compound B and Internal medicine are his primary areas of study. Alzheimer's disease is a subfield of Disease that Christopher C. Rowe studies. His Disease study incorporates themes from Biomarker, Cognition, Neuroimaging and Case-control study.
His research in Dementia intersects with topics in Cerebellar cortex, Episodic memory, Gerontology and Clinical psychology. In his research, Neocortex and Precuneus is intimately related to Posterior cingulate, which falls under the overarching field of Pathology. He has included themes like Diabetes mellitus and Oncology in his Internal medicine study.
The scientist’s investigation covers issues in Disease, Internal medicine, Alzheimer's disease, Pathology and Dementia. Christopher C. Rowe is interested in Cognitive impairment, which is a field of Disease. His Internal medicine research incorporates themes from Endocrinology, Oncology and Cardiology.
In Alzheimer's disease, Christopher C. Rowe works on issues like Neuroscience, which are connected to Neurodegeneration. Christopher C. Rowe combines subjects such as Psychiatry, Neuroimaging, Prospective cohort study and Neuropsychology with his study of Dementia. Christopher C. Rowe has researched Cognitive decline in several fields, including Cognition and Gerontology.
Christopher C. Rowe spends much of his time researching Disease, Internal medicine, Dementia, Alzheimer's disease and Cognitive decline. His Disease research is classified as research in Pathology. He focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Cardiology and, in certain cases, Magnetic resonance imaging.
His research combines Atrophy and Dementia. His work blends Alzheimer's disease and Clinical neurology studies together. His Cognitive decline research incorporates elements of Apolipoprotein E, Cognition, Neuropsychology and Cohort.
Christopher C. Rowe mostly deals with Alzheimer's disease, Internal medicine, Disease, Dementia and Cognitive decline. His Alzheimer's disease research is multidisciplinary, relying on both Biomarker, Frontotemporal lobar degeneration, Amyloid beta and Neuroscience. His Internal medicine research is multidisciplinary, incorporating perspectives in Endocrinology, Temporal lobe, Oncology and Cardiology.
His Disease research integrates issues from Positron emission tomography, Prospective cohort study and Neuroimaging. The Dementia study combines topics in areas such as Clinical syndrome, Cohort, Atrophy and Amyloid. His Cognitive decline research includes themes of Audiology, Cognition, Ageing, Apolipoprotein E and Physiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling;Paul S. Aisen;Laurel A. Beckett;David A. Bennett.
Alzheimers & Dementia (2011)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack;David A. Bennett;Kaj Blennow;Maria C. Carrillo.
Alzheimers & Dementia (2018)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois;Bruno Dubois;Howard H Feldman;Claudia Jacova;Harald Hampel;Harald Hampel.
Lancet Neurology (2014)
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Victor L. Villemagne;Samantha Burnham;Pierrick Bourgeat;Belinda M. Brown.
Lancet Neurology (2013)
Imaging beta-amyloid burden in aging and dementia.
Christopher C Rowe;Steven Ng;Uwe Ackermann;Sylvia Gong.
Neurology (2007)
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Christopher C Rowe;Kathryn A Ellis;Kathryn A Ellis;Miroslava Rimajova;Pierrick Bourgeat.
Neurobiology of Aging (2010)
β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
Kerryn Elizabeth Pike;Gregory Raymond Savage;Victor L Villemagne;Steven Ng.
Brain (2007)
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Bruno Dubois;Harald Hampel;Harald Hampel;Howard H. Feldman;Philip Scheltens.
Alzheimers & Dementia (2016)
Longitudinal Assessment of Aβ and Cognition in Aging and Alzheimer Disease
Victor L Villemagne;Kerryn E Pike;Gaël Chételat;Kathryn A Ellis.
Annals of Neurology (2011)
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease
Kathryn A Ellis;Ashley I Bush;David Darby;Daniela De Fazio.
International Psychogeriatrics (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Pittsburgh
Edith Cowan University
University of Melbourne
University of Melbourne
Florey Institute of Neuroscience and Mental Health
University of Melbourne
Florey Institute of Neuroscience and Mental Health
Monash University
Université de Caen Normandie
Yale University
Athens University of Economics and Business
University of Granada
Universitat Politècnica de Catalunya
Kyoto University
Tianjin University of Science and Technology
University of Erlangen-Nuremberg
Council of Scientific and Industrial Research
University of Colorado Denver
Aarhus University
Institut Pasteur
Mahidol University
University of California, San Diego
The Ohio State University
University of California, Los Angeles
Brown University
Institut d'Astrophysique de Paris